{"id":"https://openalex.org/W4310106489","doi":"https://doi.org/10.1182/blood-2022-170210","title":"A Real-World Single-Institution Experience with Hypomethylating Agents Plus BCL-2 Inhibitor for the Treatment of Acute Myeloid Leukemia","display_name":"A Real-World Single-Institution Experience with Hypomethylating Agents Plus BCL-2 Inhibitor for the Treatment of Acute Myeloid Leukemia","publication_year":2022,"publication_date":"2022-11-15","ids":{"openalex":"https://openalex.org/W4310106489","doi":"https://doi.org/10.1182/blood-2022-170210"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2022-170210","doi":"https://doi.org/10.1182/blood-2022-170210","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-170210","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5080775317","display_name":"Brandon J. Kale","orcid":"https://orcid.org/0009-0000-7808-7490","observed_orcids":["https://orcid.org/0009-0000-7808-7490"]},"institutions":[{"id":"https://openalex.org/I181547552","display_name":"Baylor College of Medicine","ror":"https://ror.org/02pttbw34","country_code":"US","type":"education","lineage":["https://openalex.org/I181547552","https://openalex.org/I2801539370"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brandon J Kale","raw_affiliation_strings":["1Department of Medicine, Baylor College of Medicine, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medicine, Baylor College of Medicine, Houston, TX","institution_ids":["https://openalex.org/I181547552"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113870909","display_name":"Grace S. Hwang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Grace Hwang","raw_affiliation_strings":["2Department of Pharmacy, Baylor St.Luke's Medical Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Department of Pharmacy, Baylor St.Luke's Medical Center, Houston, TX","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090817673","display_name":"Purnima Sravanti Teegavarapu","orcid":"https://orcid.org/0000-0002-5804-153X","observed_orcids":["https://orcid.org/0000-0002-5804-153X"]},"institutions":[{"id":"https://openalex.org/I181547552","display_name":"Baylor College of Medicine","ror":"https://ror.org/02pttbw34","country_code":"US","type":"education","lineage":["https://openalex.org/I181547552","https://openalex.org/I2801539370"]},{"id":"https://openalex.org/I4390039366","display_name":"Dan L Duncan Comprehensive Cancer Center","ror":"https://ror.org/02nre0x31","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I181547552","https://openalex.org/I2801539370","https://openalex.org/I4390039366"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Purnima Sravanti Teegavarapu","raw_affiliation_strings":["3Department of Hematology/Oncology, Baylor St Luke's Medical Center, Houston, TX","4Department of Medicine, Hematology/Oncology, Baylor College of Medicine, Houston, TX","5Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Department of Hematology/Oncology, Baylor St Luke's Medical Center, Houston, TX","institution_ids":[]},{"raw_affiliation_string":"4Department of Medicine, Hematology/Oncology, Baylor College of Medicine, Houston, TX","institution_ids":["https://openalex.org/I181547552"]},{"raw_affiliation_string":"5Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston, TX","institution_ids":["https://openalex.org/I4390039366"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110886100","display_name":"Martha Pritchett Mims","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I181547552","display_name":"Baylor College of Medicine","ror":"https://ror.org/02pttbw34","country_code":"US","type":"education","lineage":["https://openalex.org/I181547552","https://openalex.org/I2801539370"]},{"id":"https://openalex.org/I4390039366","display_name":"Dan L Duncan Comprehensive Cancer Center","ror":"https://ror.org/02nre0x31","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I181547552","https://openalex.org/I2801539370","https://openalex.org/I4390039366"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Martha P. Mims","raw_affiliation_strings":["3Department of Hematology/Oncology, Baylor St Luke's Medical Center, Houston, TX","4Department of Medicine, Hematology/Oncology, Baylor College of Medicine, Houston, TX","5Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Department of Hematology/Oncology, Baylor St Luke's Medical Center, Houston, TX","institution_ids":[]},{"raw_affiliation_string":"4Department of Medicine, Hematology/Oncology, Baylor College of Medicine, Houston, TX","institution_ids":["https://openalex.org/I181547552"]},{"raw_affiliation_string":"5Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston, TX","institution_ids":["https://openalex.org/I4390039366"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5059002977","display_name":"Gustavo Rivero","orcid":"https://orcid.org/0000-0002-2866-9203","observed_orcids":["https://orcid.org/0000-0002-2866-9203"]},"institutions":[{"id":"https://openalex.org/I181547552","display_name":"Baylor College of Medicine","ror":"https://ror.org/02pttbw34","country_code":"US","type":"education","lineage":["https://openalex.org/I181547552","https://openalex.org/I2801539370"]},{"id":"https://openalex.org/I4390039366","display_name":"Dan L Duncan Comprehensive Cancer Center","ror":"https://ror.org/02nre0x31","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I181547552","https://openalex.org/I2801539370","https://openalex.org/I4390039366"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gustavo Rivero","raw_affiliation_strings":["3Department of Hematology/Oncology, Baylor St Luke's Medical Center, Houston, TX","4Department of Medicine, Hematology/Oncology, Baylor College of Medicine, Houston, TX","5Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Department of Hematology/Oncology, Baylor St Luke's Medical Center, Houston, TX","institution_ids":[]},{"raw_affiliation_string":"4Department of Medicine, Hematology/Oncology, Baylor College of Medicine, Houston, TX","institution_ids":["https://openalex.org/I181547552"]},{"raw_affiliation_string":"5Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston, TX","institution_ids":["https://openalex.org/I4390039366"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2500,"currency":"USD","value_usd":2500},"apc_paid":null,"fwci":0.1792,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.51735798,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":93},"biblio":{"volume":"140","issue":"Supplement 1","first_page":"8934","last_page":"8935"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12582","display_name":"Flavonoids in Medical Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9990000128746033},{"id":"https://openalex.org/keywords/hypomethylating-agents","display_name":"hypomethylating agents","score":0.9959999918937683},{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":0.8999999761581421},{"id":"https://openalex.org/keywords/bcl2-inhibitors","display_name":"BCL-2 inhibitor","score":0.8899999856948853},{"id":"https://openalex.org/keywords/azacitidine","display_name":"azacitidine","score":0.9860000014305115},{"id":"https://openalex.org/keywords/decitabine","display_name":"decitabine","score":1.0},{"id":"https://openalex.org/keywords/elderly-patients","display_name":"elderly patients","score":0.8529999852180481},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9290000200271606},{"id":"https://openalex.org/keywords/complete-remission","display_name":"complete remission","score":0.9909999966621399},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.5109999775886536},{"id":"https://openalex.org/keywords/salvage-therapy","display_name":"salvage therapy","score":0.7009999752044678},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.6740000247955322},{"id":"https://openalex.org/keywords/age-as-prognostic-factor","display_name":"age as prognostic factor","score":0.4970000088214874},{"id":"https://openalex.org/keywords/real-world-data","display_name":"real-world data","score":0.37299999594688416}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8080363273620605},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6808071136474609},{"id":"https://openalex.org/C9583187","wikidata":"https://www.wikidata.org/wiki/Q7919510","display_name":"Ven","level":2,"score":0.6780047416687012},{"id":"https://openalex.org/C2776239401","wikidata":"https://www.wikidata.org/wiki/Q416451","display_name":"Azacitidine","level":5,"score":0.6676144599914551},{"id":"https://openalex.org/C2780235182","wikidata":"https://www.wikidata.org/wiki/Q1181878","display_name":"Decitabine","level":5,"score":0.5851956009864807},{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.5215641856193542},{"id":"https://openalex.org/C2776802502","wikidata":"https://www.wikidata.org/wiki/Q417589","display_name":"Anthracycline","level":4,"score":0.5005409717559814},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.47002291679382324},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.46321922540664673},{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.44219326972961426},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.4414437413215637},{"id":"https://openalex.org/C2776012956","wikidata":"https://www.wikidata.org/wiki/Q17125294","display_name":"Hypomethylating agent","level":5,"score":0.41044819355010986},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.37951716780662537},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.35918986797332764},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.31984978914260864},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.13938584923744202},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.08105996251106262},{"id":"https://openalex.org/C38652104","wikidata":"https://www.wikidata.org/wiki/Q3510521","display_name":"Computer security","level":1,"score":0.0},{"id":"https://openalex.org/C150194340","wikidata":"https://www.wikidata.org/wiki/Q26972","display_name":"Gene expression","level":3,"score":0.0},{"id":"https://openalex.org/C190727270","wikidata":"https://www.wikidata.org/wiki/Q874745","display_name":"DNA methylation","level":4,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2022-170210","doi":"https://doi.org/10.1182/blood-2022-170210","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-170210","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2987113244","https://openalex.org/W4409823196","https://openalex.org/W4385667139","https://openalex.org/W2983501305","https://openalex.org/W4405050710","https://openalex.org/W3215831836","https://openalex.org/W4327597315","https://openalex.org/W7093121807","https://openalex.org/W7204545476","https://openalex.org/W7204728935"],"abstract_inverted_index":{"Background:":[0],"Acute":[1],"myeloid":[2,11],"leukemia":[3],"(AML)":[4],"is":[5,409],"a":[6,33,78],"heterogeneous":[7],"clonal":[8],"disease":[9],"of":[10,35,173,211,217,271],"progenitor":[12],"cells":[13],"resulting":[14],"from":[15,80,132,145],"alterations":[16],"in":[17,111,222,229,249,267,286,353,395],"cell":[18],"differentiation,":[19],"proliferation,":[20],"and":[21,27,37,52,71,98,114,138,187,226,239,357,391,411],"renewal.":[22],"Treatment":[23],"for":[24,43,68,201,244,284,305,323,338],"young":[25],"patients":[26,70,131,152,213,218,356],"those":[28,115,287,297,306,324,339,358,370],"with":[29,60,84,101,116,193,206,307,325,340,359,372],"favorable-to-intermediate":[30],"risk":[31,118,126,237,361,381,398],"remains":[32],"combination":[34,54],"cytarabine":[36],"anthracycline,":[38],"while":[39],"the":[40,44,112,122,223,230,268,396],"optimal":[41],"regimen":[42],"elderly":[45,113,269,355],"has":[46,65],"yet":[47],"to":[48,93,108,147,369],"be":[49],"established.":[50],"First-line":[51],"salvage":[53],"hypomethylating":[55],"agents":[56],"azacitidine":[57],"or":[58,102],"decitabine":[59],"BCL-2":[61],"inhibitor":[62],"venetoclax":[63],"(HMA+Ven)":[64],"shown":[66],"promise":[67],"these":[69],"are":[72],"becoming":[73],"standard":[74,159],"therapy.":[75,88,374],"We":[76,89],"present":[77],"cohort":[79,251],"our":[81,250,354],"institution":[82],"treated":[83,205,371],"HMA+Ven":[85,91,156,174,207,224,240,253,274,285,312,330,337,349,407],"vs":[86,254,261,277,291,301,315,345],"traditional":[87,109,373],"hypothesize":[90],"leads":[92],"improved":[94],"overall":[95,320],"survival":[96,162,245,266,321,408],"(OS)":[97],"complete":[99],"remission":[100],"without":[103],"count":[104],"recovery":[105],"(CR/CRi)":[106],"compared":[107,368],"therapy":[110],"unfavorable":[117,360],"as":[119,294,296,364,366],"defined":[120],"by":[121,155,167,181,385,402],"European":[123],"LeukemiaNet":[124],"(ELN-2017)":[125],"stratification.":[127],"Methods:":[128],"232":[129],"AML":[130],"Baylor":[133],"St.":[134],"Lukes":[135],"Medical":[136,143],"Center,":[137],"Michael":[139],"E":[140],"DeBakey":[141],"VA":[142],"Center":[144],"8/26/1997":[146],"7/31/2021":[148],"were":[149,153,242],"reviewed.":[150],"These":[151],"stratified":[154],"vs.":[157],"other":[158,231,255],"treatment.":[160],"Differential":[161],"among":[163],"groups":[164],"was":[165,179,199,219,282,392],"measured":[166],"Kaplan-Meier":[168],"method.":[169],"The":[170,400],"independent":[171],"effect":[172],"against":[175],"multiple":[176],"intervening":[177,191],"variables":[178,192],"evaluated":[180],"Cox":[182],"proportional":[183],"regression":[184,387],"analysis.":[185,202],"Chi-square":[186],"t-test":[188],"detected":[189],"potential":[190],"impact":[194],"on":[195],"outcome.":[196],"SAS":[197],"software":[198],"used":[200],"Results:":[203],"Those":[204],"comprised":[208],"28":[209],"out":[210],"227":[212],"(12.3%).":[214],"Average":[215],"age":[216,288,298],"65":[220],"(26-80)":[221],"group":[225,233],"61.3":[227],"(20-93)":[228],"treatment":[232,241,256],"(p=0.05).":[234],"Age,":[235],"ELN-2017":[236,309,380],"stratification,":[238],"predictors":[243],"(Table":[246,389],"1).":[247],"OS":[248,304,363],"favors":[252,273,311,329,336],"(Fig.":[257],"1,":[258],"348":[259],"days":[260,276,314],"261":[262],"days,":[263,279,317],"p=0.0004).":[264],"Overall":[265],"population":[270],"interest":[272],"(270":[275],"135":[278],"p<0.0001).":[280],"CR/CRi":[281,335],"superior":[283,351],">60":[289],"(55%":[290,300],"24.7%,":[292],"p=0.006)":[293],"well":[295,365],">70":[299],"15.2%":[302],"p=0.007).":[303],"adverse":[308,397],"stratification":[310],"(352":[313],"164":[316],"p=.002).":[318],"Interestingly,":[319],"trends":[322],"active":[326],"smoking":[327,404],"history":[328],"(p<0.0001).":[331],"Lastly":[332],"we":[333],"found":[334],"RUNX1":[341],"gene":[342],"mutation":[343],"(75%":[344],"25%,":[346],"p=0.01).":[347],"Conclusion:":[348],"demonstrated":[350],"response":[352],"through":[362],"CR/CRi,":[367],"This":[375],"held":[376],"true":[377],"across":[378],"all":[379],"categories":[382],"when":[383],"examined":[384],"cox":[386],"models":[388],"1)":[390],"most":[393],"notable":[394],"subgroup.":[399],"mechanism":[401],"which":[403],"may":[405],"enhance":[406],"uncharacterized":[410],"warrants":[412],"investigation.":[413],"Figure":[414],"1View":[415,418],"largeDownload":[416,419],"PPTFigure":[417],"PPT":[420],"Close":[421],"modal":[422]},"counts_by_year":[{"year":2024,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-11-30T00:00:00"}